Literature DB >> 30025274

Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey.

Maia Thrift-Perry1, Anna Cabanes2, Fatima Cardoso3, Katherine Moose Hunt4, Tauane Araújo Cruz4, Kyra Faircloth1.   

Abstract

Metastatic breast cancer (mBC) is an area with high unmet need across the world. Despite significant progress to meet patient need, current breast cancer (BC) policies fail to recognize the unique challenges of patients who are further along the cancer patient journey. This analysis aims to understand BC/mBC policy development at a global level and identify opportunities for further development. A comprehensive analysis of National Cancer Control Plans (NCCPs) policies and programs was conducted across 16 countries, which represent a diverse range of healthcare systems, economies and geographic regions. Examples of promising practices, implemented or initiated by civil society, are provided to demonstrate successful methods to address the identified policy gaps. The analysis finds that disparities in BC policy development exist across and within countries. Progress in BC policy is fragmented and skewed towards the early part of the patient journey e.g. awareness and stakeholder education, with key gaps remaining in diagnosis and patient identification. In addition, access to innovative mBC treatments, ongoing support and palliative care remain a challenge, while care coordination is limited due to inefficient referrals. Although government and policymaker action is fundamental, collaboration between different stakeholders is imperative to address unmet needs of BC/mBC patients alike. Policy initiatives and promising practices that demonstrate successful multi-stakeholder engagement can be replicated or used to inform further advocacy and policy development with the aim to address patient unmet needs.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Advocacy; Breast cancer; Implementation; Metastatic breast cancer; National cancer control plan; Policy

Mesh:

Year:  2018        PMID: 30025274     DOI: 10.1016/j.breast.2018.06.005

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  6 in total

1.  Sex-Specific Patient Journeys in Early Parkinson's Disease in the Netherlands.

Authors:  Floris Pieter Vlaanderen; Yvonne de Man; Jesse H Krijthe; Marit A C Tanke; A S Groenewoud; Patrick P T Jeurissen; Sabine Oertelt-Prigione; Marten Munneke; Bastiaan R Bloem; Marjan J Meinders
Journal:  Front Neurol       Date:  2019-07-30       Impact factor: 4.003

2.  Smart health via mHealth? Potentials of mobile health apps for improving prevention and adherence of breast cancer patients.

Authors:  Stefanie Scholz; Laura Teetz
Journal:  Digit Health       Date:  2022-01-20

3.  Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.

Authors:  Robert S Miller; Stella Mokiou; Aliki Taylor; Ping Sun; Katherine Baria
Journal:  Breast Cancer Res Treat       Date:  2022-02-22       Impact factor: 4.872

4.  National Policies to Prevent and Manage Cervical Cancer in East African Countries: A Policy Mapping Analysis.

Authors:  Diana Wangeshi Njuguna; Nour Mahrouseh; Dede Onisoyonivosekume; Orsolya Varga
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

5.  Prevalence, trend and disparities of palliative care utilization among hospitalized metastatic breast cancer patients who received critical care therapies.

Authors:  Ying Chen; Shuchen Lin; Yihui Zhu; Rui Xu; Xiaohong Lan; Fang Xiang; Xiang Li; Ye Zhang; Shudong Chen; Hao Yu; Dongni Wu; Juxiang Zang; Jiali Tang; Jiewen Jin; Hedong Han; Zhonghua Tao; Yonggang Zhou; Xichun Hu
Journal:  Breast       Date:  2020-11-07       Impact factor: 4.380

Review 6.  A Narrative Review of the Patient Journey Through the Lens of Non-communicable Diseases in Low- and Middle-Income Countries.

Authors:  Ratna Devi; Komal Kanitkar; R Narendhar; Kawaldip Sehmi; Kannan Subramaniam
Journal:  Adv Ther       Date:  2020-10-14       Impact factor: 4.070

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.